GlassScriptPhysician profile
Reagan E Bristol
NPI 1578536199
$5,553.86
in general payments reported to CMS, 2019-2025
27 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $421 · 2021: $438 · 2022: $840 · 2023: $1,038 · 2024: $1,187 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,647.64 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $968.48 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $439.06 | 2021-2025 | |
| Pfizer INC. | $366.35 | 2019-2023 | |
| Novo Nordisk INC | $321.36 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $263.87 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.21 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $147.88 | 2022-2025 | Rexulti |
| Allergan, INC. | $136.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $116.34 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Harmony Biosciences LLC | $114.58 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.92 | 2020-2022 | |
| Dexcom, INC. | $102.25 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $83.53 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $79.56 | 2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $77.17 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $63.37 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $59.23 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $54.48 | 2019-2020 | |
| Horizon Therapeutics Plc | $52.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.66 | 2022 | |
| Neurocrine Biosciences, INC. | $30.55 | 2023-2024 | Ingrezza |
| Corcept Therapeutics | $19.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.96 | 2020 | |
| Scpharmaceuticals INC. | $14.46 | 2025 | |
| Amgen INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Bristol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.